Analyst Downgrades – La Jolla Pharmaceutical (NASDAQ:LJPC) Stock Gets Downgraded By Jefferies Group from Buy to Underperform

ME Staff
-
0

Analyst Ratings For La Jolla Pharmaceutical (NASDAQ:LJPC)

Today, La Jolla Pharmaceutical (NASDAQ:LJPC) stock was downgraded by Jefferies Group from Buy to Underperform.

Some recent analyst ratings include

  • 2/12/2018-Jefferies Group was Downgraded by analysts at Jefferies Group from a “Buy ” rating to a ” Underperform” rating.
  • 12/22/2017-Cowen Reiterated Rating of Buy.
  • 12/22/2017-JPMorgan Chase & Co. Reiterated Rating of Sell.
  • 4/30/2017-Noble Financial Reiterated Rating of Buy.


  • On 12/29/2017 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
  • On 12/29/2017 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
  • On 12/27/2017 Jennifer Carver, COO, bought 1,000 with an average share price of $33.22 per share and the total transaction amounting to $33,220.00.
  • On 12/27/2017 Jennifer Carver, COO, bought 1,000 with an average share price of $33.22 per share and the total transaction amounting to $33,220.00.
  • On 3/23/2017 Kevin C Tang, Director, bought 149,254 with an average share price of $33.50 per share and the total transaction amounting to $5,000,009.00.
  • On 3/3/2017 Dennis Mulroy, CFO, bought 500 with an average share price of $33.95 per share and the total transaction amounting to $16,975.00.
  • On 3/3/2017 George F Tidmarsh, CEO, bought 3,000 with an average share price of $34.17 per share and the total transaction amounting to $102,510.00.

Recent Trading Activity for La Jolla Pharmaceutical (NASDAQ:LJPC)
Shares of La Jolla Pharmaceutical closed the previous trading session at 34.52 down -2.31 6.27% with 297278 shares trading hands.